Prostaglandin E-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment by unknown
Inflammation and RegenerationAoki and Narumiya Inflammation and Regeneration  (2017) 37:4 
DOI 10.1186/s41232-017-0036-7REVIEW Open AccessProstaglandin E2-EP2 signaling as a node of
chronic inflammation in the colon tumor
microenvironment
Tomohiro Aoki* and Shuh NarumiyaAbstract
Background: Colorectal cancer is the third most common cancer. Involvement of prostaglandin (PG) system in the
pathogenesis of colorectal cancer has been suggested from clinical studies demonstrating therapeutic effect of
NSAIDs including aspirin or selective COX-2 inhibitors. However, mechanisms on how PG regulates inflammatory
responses leading to colorectal cancer development remain obscure. Further, careful attention is needed to use
these drugs for a long time because of adverse effects due to non-specific inhibition of physiological PG production in
addition to pathological one, making the development of alternatives to aspirin important. Recent studies using mouse
model of colitis-associated colon cancer, azoxymethane (AOM)-dextran sodium sulfate (DSS) model, have revealed some
of the mechanisms on how PG regulates inflammation in lesions and proposed PG receptor as a therapeutic target.
Main body of abstract: Among each PG receptor subtype examined, prostaglandin E receptor 2 (EP2) signaling
specifically contributes to colorectal cancer formation and inflammation in lesions of AOM-DSS model. EP2 is
expressed in neutrophils, infiltrated major inflammatory cells, and tumor-associated fibroblasts (TAFs) in the tumor
stroma of this mouse model and also in clinical specimen from ulcerative colitis-associated colorectal cancer.
Bone marrow transfer experiments between wild-type and EP2-deficient mice have confirmed the involvement of
EP2 signaling in these two types of cells in the pathogenesis of the disease. EP2 signaling in both types of cells
regulates the transition to and maintenance of inflammation in multiple steps to shape the tumor microenvironment
which contributes to trigger and promote colorectal cancer. In this process, PGE2-EP2 signaling synergizes with TNF-α
to amplify TNF-α-induced inflammatory responses, forms a positive feedback loop involving COX-2-PGE2-EP2 signaling
to exacerbate PG-mediated inflammation once triggered, and alternates active cell populations participating in
inflammation through forming self-amplification loop among neutrophils. Thus, EP2 signaling functions as a node
of inflammatory responses in the tumor microenvironment. Based on such a notion, EP2 can become a strong
candidate for therapeutic target of colorectal cancer treatment. Indeed, in AOM-DSS model, a selective EP2
antagonist, PF-04418948, potently suppresses colorectal tumor formation.
Short conclusion: PGE2-EP2 signaling functions as a node of chronic inflammation which shapes the tumor
microenvironment and thus is a strong candidate of target for the chemoprevention of colorectal cancer.
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Prostaglandins (PGs) including PGD2, PGE2, PGF2α,
PGI2, and thromboxane (TX) A2 are arachidonic acid
metabolites formed by sequential actions of cyclooxy-
genase (COX) and respective synthases for each PG and
exert their actions by acting on their cognate G-protein-
coupled receptors (GPCRs) [1]. PGs are traditionally rec-
ognized as a major mediator of acute inflammatory
responses because non-steroidal anti-inflammatory
drugs (NSAIDs), which inhibit the activity of COX and
shut off PG production, effectively suppress symptoms
of acute inflammation: fever, reddish, swelling, and pain.
Interestingly, recent experimental studies mainly using
mice deficient in each PG receptor subtype subjected to
animal disease models have revealed the involvement of
PG system and its receptor signaling in the pathogen-
esis of various diseases with chronic course such as
cancer, vascular diseases, or neurodegenerative diseases
and thereby suggested the regulation of not only acute
inflammation but also chronicity of inflammation by
PGs [2].
Colorectal cancer is the third common cancer [3]. One
of the major risk factors of colorectal cancer is inflam-
matory bowel diseases such as ulcerative colitis [4], indi-
cating the involvement of inflammatory responses in the
pathogenesis of colorectal cancer. Indeed, in 1988,
reduction of the risk of colorectal cancer development in
aspirin users was reported [5]. Subsequently, some clin-
ical studies reported reduction of the risk and mortality
of colorectal cancer by the use of NSAIDs including
aspirin [6–8], suggesting the close association of the
pathogenesis of colorectal cancer with PG-mediated in-
flammation. Up to now, contribution of PG system to
colon cancer cells has been extensively studied mainly
using cancer cell lines, i.e., prostaglandin E receptor 2
(EP2) signaling promotes growth of colon cancer cells
via driving a Gs-axin-b-catenin axis in vitro [9]. Al-
though inflammation in the tumor microenvironment,
where many types of cells interact with tumor cells, is
essential to promote their development and growth,
studies addressing how PG system regulates this inflam-
mation in the tumor microenvironment of colorectal
cancer in detail are quite limited [10, 11].
In this short review, we explain and interpret our re-
cent experimental findings regarding the regulation of
chronic inflammatory responses in the tumor micro-
environment of colorectal cancer by PGE2-EP2 signaling
cascade [12].
Prostaglandin system as a node of inflammation in tumor
environment and its contribution to colon tumor
formation
To analyze the contribution of PG system to inflamma-
tory responses in the tumor microenvironment andsubsequent colon tumor formation, we used colitis-
associated colorectal cancer model of mice, in which
tumor is induced in the colon by the combination of ad-
ministration of carcinogen, azoxymethane (AOM), with
dextran sodium sulfate (DSS) to induce colitis [13].
Among the PG receptor subtypes examined, genetic de-
letion of EP2 (Ptger2) specifically and almost completely
suppressed colon tumor formation in AOM-DSS model
of mice [12]. Intriguingly, deletion of EP1 (Ptger1), EP3
(Ptger3), or some other PG receptor subtypes failed to
suppress colon tumor formation but rather exacer-
bated it, suggesting the presence of PG receptor sub-
type oppositely functioning to colon tumor formation.
Consistently, genetic deletion of mPGES-1 (Ptges), an
enzyme producing PGE2, remarkably suppressed colon
tumor formation, but the number of tumors induced
in this mouse line was still significantly larger than
that in EP2-deficient mice [12]. These experimental
findings suggest the superiority of antagonism-
targeting EP2 over non-specific inhibition of PG re-
ceptors through suppression of PGE2 production by
NSAIDs or selective COX-2 inhibitors. Histopatho-
logical analyses revealed the remarkable reduction of
inflammatory infiltrates accompanied with relatively
conserved crypts in the colon of EP2-deficient mice.
The majority of these inflammatory infiltrates is neu-
trophil, defined as a CD45+CD11b+Ly-6G+ cell, and
deficiency of EP2 significantly decreased its number in
the colon [12], suggesting the role of EP2 signaling in
neutrophil infiltration into the colon and regulation of
neutrophil-mediated inflammatory responses in le-
sions. In immunohistochemical analysis, EP2 expres-
sion was detected in these neutrophils and also in
tumor-associated fibroblasts (TAFs) in mesenchyme
[12]. In human specimen from ulcerative colitis-
associated colorectal cancer, EP2 expression could be
detected similarly in neutrophils and TAFs, suggesting
the clinical relevance. In accordance with the expres-
sion of EP2 on neutrophils and TAFs, bone marrow
transfer experiments between wild-type and EP2-
deficient mice revealed the significant contribution of
EP2 expressed on both recipient and donor cells [12].
In both cell types, EP2 signaling plays a role as a regu-
lator of inflammatory responses. First, in in vitro
study, EP2 signaling synergizes with other cytokines
present in the tumor microenvironment, TNF-α, to
transcriptionally induce expressions of IL-6 (Il6),
COX-2 (Ptgs2), and CXCL1 (Cxcl1) in primary culture
of neutrophils and IL-6, COX-2, and MMP-12
(MMP12) in 18 Co cell line, an in vitro TAF model
[12]. Intriguingly, EP2 signaling alone only slightly in-
duces these expressions. The in vivo relevance of these
findings also demonstrated that deficiency in EP2 sup-
presses expressions of pro-inflammatory molecules,
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cell growth, such as osteopontin, in lesions [12]. In
other words, EP2 signaling amplifies TNF-α-induced
expressions of pro-inflammatory factors like IL-6 as a
“cytokine amplifier” [12]. Second, as described above,
EP2 signaling induces COX-2 expression both in neu-
trophils and 18 Co cells synergistically with TNF-α
in vitro [2, 12]. Consistently, because expressions of
both EP2 and COX-2 are induced and become detect-
able in neutrophils and TAFs in the colon of AOM-
DSS model during the development of the disease and
genetic deletion of EP2 greatly suppressed COX-2
expression in these two types of cells [12], EP2 and
COX-2 presumably have inter-dependency in vivo. As
COX-2 is an inducible form of a PG-producing
enzyme, induction of this enzyme under EP2 signaling
means the formation of a positive feedback loop includ-
ing COX-2-PGE2-EP2 signaling cascade. Such a forma-
tion of a positive feedback loop makes PG-mediated
inflammatory responses once triggered long-lasting and
being exacerbated. Third, in primary culture of neutro-
phils, EP2 signaling induced their own chemoattractant,
CXCL1, synergistically with TNF-α [12]. In the colon of
AOM-DSS model, CXCL1 expression was mainly de-
tectable in infiltrated neutrophils and its expression
was remarkably and significantly ameliorated in EP2-Fig. 1 Regulation of inflammatory responses in the tumor microenvironme
tumor environment in multiple steps, i.e., (1) the synergistic induction of cy
and neutrophils with TNF-α, (2) the formation of a positive feedback loop i
triggered, (3) the induction of CXCL1 to recruit neutrophils and alternate activ
loop among neutrophilsdeficient mice [12], suggesting the regulation of CXCL1
expression by EP2 signaling also in vivo as in in vitro.
EP2-mediated CXCL1 expression alternates active cell
populations participating in inflammatory responses in
situ via infiltrating neutrophils and thereby contributing
to the configuration of the microenvironment where
inflammation triggers/promotes tumorigenesis. Intri-
guingly, CXCL1 is produced from neutrophils both in
in vitro and in vivo, suggesting the formation of a self-
amplification loop among neutrophils which further ex-
acerbates and prolongs inflammation.
In summary, PGE2-EP2 signaling plays a role as a node
of inflammation in the tumor microenvironment to
amplify inflammatory responses which support tumor
development and progression. In this process, this EP2
signaling contributes to the chronicity of inflammation
in multiple steps (Fig. 1), i.e., (1) the formation of a posi-
tive feedback loop to exacerbate PG-mediated inflamma-
tory responses, (2) the function as a “cytokine amplifier,”
and (3) the alternation of active cell populations in situ
partially through forming a self-amplification loop
among neutrophils. Such a role of EP2 or PG receptor
signaling on chronicity of inflammation can be observed
also in the microenvironment of various inflammatory
settings, and thus, PG system contributes to the patho-
genesis of various diseases as a node of inflammatorynt of colon cancer by PGE2-EP2 signaling. PGE2-EP2 signaling shapes
tokines and growth factors from tumor-associated fibroblasts (TAFs)
nvolving COX-2-PGE2-EP2 signaling to exacerbate inflammation once
e cell populations in situ, and (4) the formation of a self-amplification
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in more detail, understanding of PG system as a major
regulator of inflammation in not only acute but also
chronic one is conceptually important for our under-
standing of the pathogenesis underlying various diseases
and also as a translational research to develop novel
therapeutic drugs targeting inflammatory diseases.
Potential of EP2 as a therapeutic target to treat colorectal
cancer
As described above, EP2 signaling plays a crucial role in
colon tumorigenesis as a node of inflammation in the
tumor microenvironment. Thereby, EP2 may be a strong
candidate as a therapeutic target for the treatment of
colorectal cancer especially with active inflammatory re-
sponses in the stroma. The potential of pharmacological
inhibition of EP2 signaling as a therapeutic measure for
colorectal cancer treatment is therefore examined in
AOM-DSS model of mice [12]. A selective EP2 antagon-
ist, PF-04418948 [14, 15], is administered to mice sub-
jected to AOM-DSS model, and colon tumor formation
in this model is then examined. As a result, PF-
04418948 dose dependently (1–100 mg/kg) suppresses
the number of colon tumor, and notably at the highest
dose of this compound (100 mg/kg), any colon tumor is
induced [12]. Consistent with the EP2-mediated forma-
tion of a self-amplification loop among neutrophils via
secretion of their chemoattractant CXCL1, infiltration of
inflammatory cells and expression of CXCL1 in the
lesion are both remarkably suppressed in PF-
04418948-treated mice [12]. A selective EP2 antagonist
can therefore become a strong candidate for drugs to
treat colorectal cancer or prevent the initiation/recur-
rence of it via acting on inflammatory responses in
situ. Here, it should be carefully discussed that
NSAIDs and COX-2 inhibitors have significant adverse
effects such as gastrointestinal hemorrhage and car-
diovascular accidents [16] derived from a non-specific
inhibition of PG receptors, some of which mediates a
physiological function to maintain homeostasis of or-
gans, and impaired balance between PGI2 and TXA2,
respectively. Indeed, deficiency in COX-1 or COX-2
potentiates injury in the colon epithelium under treat-
ment with DSS in mice [17]. Also, other anti-
inflammatory drugs such as those targeting IL-6 and
TNF-α have a potential risk of development of infec-
tious and other types of cancers. Considered with nor-
mal development of EP2-deficient mice except for
impaired fertilization [18] and the induced expression
of EP2 selectively in lesions, a selective EP2 antagonist
can be a safer and potent alternative to aspirin and
other anti-inflammatory drugs in the chemoprevention
of colorectal cancer. Further, because the use of aspirin
reduces the risk of death from all cancers includingcolorectal cancer, lung cancer, and esophageal cancer
[19] and high expression of EP2 in tumor lesions have
a positive correlation with poor outcome in some can-
cers [20, 21], a selective EP2 antagonist can also be a
strong candidate as a therapeutic drug to treat a var-
iety of cancers.
Conclusions
Colorectal cancer is considered as a PG-mediated path-
ology through various clinical studies which have dem-
onstrated the therapeutic effect of NSAIDs or selective
COX-2 inhibitors on this disease. We addressed mecha-
nisms on how PG system regulates colon tumorigenesis,
and our recent experimental findings using AOM-DSS
model in mice have demonstrated the involvement of
PGE2-EP2 system in the pathogenesis of colorectal can-
cer. EP2 expresses in infiltrated neutrophils and TAFs in
the tumor microenvironment, and this signaling plays a
role to maintain inflammatory responses in the colon to
form a microenvironment supporting the initiation and
promotion of cancer cells. The processes EP2 signaling
regulates such as the maintenance of inflammation in-
clude the formation of a positive feedback loop to amp-
lify PG-mediated inflammation, the amplification of
inflammation synergistically with other cytokines, and
the alternation of cell populations participating in situ.
Further, we propose the potential of a selective EP2
agonist as a safer alternative to aspirin.
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